[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 885600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 402304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 45625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sheng  Cui Ph.D.", "title": "Chief Manufacturing Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 20.91, "open": 20.74, "dayLow": 20.07, "dayHigh": 21.31, "regularMarketPreviousClose": 20.91, "regularMarketOpen": 20.74, "regularMarketDayLow": 20.07, "regularMarketDayHigh": 21.31, "payoutRatio": 0.0, "beta": -0.056, "forwardPE": -11.111112, "volume": 1120480, "regularMarketVolume": 1120480, "averageVolume": 886801, "averageVolume10days": 755550, "averageDailyVolume10Day": 755550, "bid": 20.83, "ask": 21.06, "bidSize": 1, "askSize": 6, "marketCap": 2306178048, "fiftyTwoWeekLow": 15.19, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 50.61515, "fiftyDayAverage": 22.7744, "twoHundredDayAverage": 19.769775, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1472432000, "profitMargins": 0.0, "floatShares": 53676750, "sharesOutstanding": 109818000, "sharesShort": 2911595, "sharesShortPriorMonth": 2991295, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.0269, "heldPercentInsiders": 0.00397, "heldPercentInstitutions": 0.9908, "shortRatio": 4.49, "shortPercentOfFloat": 0.040900003, "impliedSharesOutstanding": 109818000, "bookValue": 7.01, "priceToBook": 2.9957204, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -241598000, "trailingEps": -2.56, "forwardEps": -1.89, "enterpriseToRevenue": 32.316, "enterpriseToEbitda": -8.358, "52WeekChange": -0.092841625, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 21.0, "targetHighPrice": 51.368217, "targetLowPrice": 35.312984, "targetMeanPrice": 43.3812, "targetMedianPrice": 44.45344, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 834190016, "totalCashPerShare": 7.596, "ebitda": -176176000, "totalDebt": 448000, "quickRatio": 8.001, "currentRatio": 8.075, "totalRevenue": 45563000, "debtToEquity": 0.059, "revenuePerShare": 0.483, "returnOnAssets": -0.18186001, "returnOnEquity": -0.46199, "grossProfits": 45563000, "freeCashflow": -43394624, "operatingCashflow": -158564000, "revenueGrowth": 14.905, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -3.38467, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "corporateActions": [], "postMarketTime": 1740790642, "regularMarketTime": 1740776400, "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.4304168, "regularMarketPrice": 21.0, "fiftyTwoWeekLowChangePercent": 0.38248852, "fiftyTwoWeekRange": "15.19 - 27.29", "fiftyTwoWeekHighChange": -6.290001, "fiftyTwoWeekHighChangePercent": -0.23048738, "fiftyTwoWeekChangePercent": -9.2841625, "epsTrailingTwelveMonths": -2.56, "epsForward": -1.89, "epsCurrentYear": -1.81683, "priceEpsCurrentYear": -11.558594, "fiftyDayAverageChange": -1.7744007, "fiftyDayAverageChangePercent": -0.07791207, "twoHundredDayAverageChange": 1.2302246, "twoHundredDayAverageChangePercent": 0.062227547, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-02-28", "averageAnalystRating": "1.5 - Strong Buy", "marketState": "CLOSED", "firstTradeDateMilliseconds": 1612881000000, "hasPrePostMarketData": true, "postMarketChangePercent": 5.04762, "postMarketPrice": 22.06, "postMarketChange": 1.06, "regularMarketChange": 0.09000015, "regularMarketDayRange": "20.07 - 21.31", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 886801, "fiftyTwoWeekLowChange": 5.8100004, "cryptoTradeable": false, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]